AUTHOR INDEX

(P = Proceedings)

AARONS, L. *see* DAVIS, J. D.
ABEL, S. M. *see* BROCKLESBY, K.
ACUFF, A. E. *see* HE, G.-W.
AELLIG, W. H. Clinical pharmacology, physiology and pathophysiology of superficial veins—1, 181
AELLIG, W. H. Clinical pharmacology, physiology and pathophysiology of superficial veins—2, 289
ALLAM, A. *see* GROVE, A.
ALM, C. *see* BERTILSSON, L.
ANDERSON, J. *see* BARKER, J. E.
ANDERSSON, A. *see* WALLEN, N. H.
ANDERSSON, T., MINERS, J. O., VERONESE, M. E. & BIRKETT, D. J. Diazepam metabolism by human liver microsomes is mediated by both S-mephenytoin hydroxylase and CYP3A isoforms, 131
ANNUS, T. *see* DYER, J. R.
ARANKO, K., LUURILA, H., BACKMAN, J. T., NEUVONEN, P. J. & OLKKOLA, K. T. The effect of erythromycin on the pharmacokinetics and pharmacodynamics of zopiclone, 363
ASTHANA, O. P. *see* PALIWAL, J. K.
AUSTIN, C. E. *see* SCADDING, G. K.
AVIRAM, M. *see* KEIDAR, S.
AYRTON, A. D. *see* BALDWIN, S. J.
AYRTON, A. D. *see* BLOOMER, J. C.
AYRTON, A. D. *see* CLARKE, S. E.
AYRTON, J. *see* EVANS, G. L.

BACK, D. J. *see* BROCKLESBY, K.
BACK, D. J. *see* HOGGARD, P. G.
BACK, D. J. *see* VEAL, G. J.
BACKMAN, J. T. *see* ARANKO, K.
BADER, A., CHRISTIANS, U., CROME, O., FRÜHAUF, N., ESSELMANN, H. & SEWING, K. Fr. Use of organotypical cultures of primary hepatocytes to study drug biotransformation, 158P
BALDWIN, S. J. *see* BLOOMER, J. C.
BALDWIN, S. J. *see* CLARKE, S. E.
BALDWIN, S. J., BLOOMER, J. C., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. & CHENERY, R. J. The use of sulphaphenazole as a potent and specific inhibitor of cytochrome P450 2C9 *in vitro*, 174P
BALL, D. E., MCLAUGHLIN, W. S., SEYMOUR, R. A. & KAMALI, F. Comparison of *in vitro* and *in vivo* metabolism of phenytoin in the rat, cat and man and susceptibility to phenytoin-induced gingival overgrowth, 168P
BANGA, J. D. *see* JACOTOT, B.
BARKER, J. E., ANDERSON, J., TREASURE, T. & PIPER, P. J. Influence of endothelium and surgical preparation on responses of human saphenous vein and internal thoracic artery to angiotensin II, 57
BARRY, M. G. *see* VEAL, G. J.
BASCI, N. E., BROSEN, K., BOZHURT, A., ISIMER, A., SAYAL, A. & KAYAALP, S. O. S-mephenytoin, sparteine and debrisoquine oxidation: genetic polymorphisms in a Turkish population, 463
BATEMAN, D. N. *see* ROBERTS, S. J.
BAUMANN, J. *see* GONSCHIOR, A.-K.
BAUMANN, P., HATZINGER, M., HEMMETER, U., SEIFRITZ, E., EAP, C. B. & HOLSBOER, E. Letter to the Editor: Influence of amesergide treatment on the dextromethorphan test, 151
BAUSE, H. *see* SCHOLZ, J.
BAXTER, G. F. & YELLON, D. M. Review: Ischaemic preconditioning of myocardium: a new paradigm for clinical cardioprotection?, 381
BEAUMONT, K. C., MACRAE, P. V., MILLER, C. M., WRIGHT, P. A. & SMITH, D. A. Pharmacokinetics of zamifenacin in man and animals: species differences in plasma protein binding, 179P
BEDDING, A. W. *see* PARIKH, R.
BECKER, K. *see* FUHR, U.
BEEDHAM, C. *see* RASHIDI, M. R.
BEGAUD, B., MORIDE, Y., TUBERT-BITTER, P., CHASLERIE, A. & HARAMBURU, F. False-positives in spontaneous reporting: should we worry about them?, 401
BEITINGER, H. *see* STORM, G.
BELZ, G. G. *see* DE MEY, C.
BENDER, N. *see* COCKCROFT, J. R.
BENITEZ, J. *see* BERTILSSON, L.
BENJAMIN, N. *see* LYONS, D.
BERNUS, I., DICKINSON, R. G., HOOPER, W.D. & EADIE, M. J. Inhibition of phenobarbitone *N*-glucosidation by valproate, 411
BERTAGNA, X. *see* COSTE, J.
BERTILSSON, L., CARRILLO, J. A., DAHL, M.-L., LLERENA, A., ALM, C., BONDESSON, U., LINDSTROM, L., RODRIGUEZ DE LA RUBIA, I., RAMOS, S. & BENITEZ, J. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test, 471
BESSA, E. *see* JACQZ-AIGRAIN, E.
BILLON, N. *see* DIMIER-DAVID, L.
BIRKETT, D. J. *see* ANDERSSON, T.
BLOOMER, J. C. *see* BALDWIN, S. J.
BLOOMER, J. C. *see* CLARKE, S.E.
BLOOMER, J. C., BALDWIN, S. J., SMITH, G. J., AYRTON, A. D., CLARKE, S. E. & CHENERY, R. J. Characterisation of the cytochrome P450 enzymes involved in the *in vitro* metabolism of granisetron, 557
BLOOMER, J. C., CLARKE, S. E., BALDWIN, S. J., SMITH, G. J., AYRTON, A. D. & CHENERY, R. J. Characterisation of granisetron metabolism in human liver microsomes, 173P
BOCHNER, F. *see* KERRY, N. L.
BONDESSON, U. *see* BERTILSSON, L.
BOWMAN, A. J., CHEN, C. P. L.-H. & FORD, G. A. Nitric oxide mediated venodilator effects of nebivolol, 199
BOZHURT, A. *see* BASCI, N. E.
BRADBURY, A. *see* WORBOYS, P. D.
BRATTY, J. R. *see* BYROM, W. D.
BRAUN, F. *see* GONSCHIOR, A.-K.
BRECKENRIDGE, A. M. *see* WALLER, P. C.
BREITHAUPT-GROGLER, K. *see* DE MEY, C.
BRENNAN, B. *see* DAVIS, J. D.
BRETT, S. E. *see* COCKCROFT, J. R.
BREUEL, H.-P. *see* HEINE, P. R.
BROCKLESBY, K. *see* HEWITT, P.
BROCKLESBY, K., ABEL, S. M., HOTCHKISS, S. A. M. & BACK, D. J. Absorption and metabolism of hydrocortisone in human skin *in vitro*, 164P
BROOK, J. G. *see* KEIDAR, S.
BROSEN, K. *see* BASCI, N. E.
BROWN, V. *see* WATTS, P.
BRUCE-JONES, P. N. E., CROME, P. & KALRA, L. Indomethacin and cognitive function in healthy elderly volunteers, 45
BRUNDIN, R. M. *see* GRAHNEN, A.
BURKE, M. D. *see* EKINS, S.
BURKE, M. D. *see* MALEY, M.
BURM, A. G. L., VAN DER MEER, A. D., VAN KLEEF, J. W., ZEIJLMANS, P. W. M. & GROEN, K. Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate, 125
BYROM, W. D., ROTHERHAM, N. E. & BRATTY, J. R. Relationship between hypoglycaemic response and plasma concentrations of BTS 67 582 in healthy volunteers, 433

CALDWELL, J. *see* GUILLOU, F.
CALDWELL, J. *see* STRIBBLING, S. M.
CARGILL, R. I., COUTIE, W. J. & LIPWORTH, B. J. The effects of angiotensin II on circulating levels of natriuretic peptides, 139

CARLILE, D. J., DICKINS, M. & HOUSTON, J. B. Scaling factors for predicting the kinetics of drug metabolism *in vivo* using *in vitro* systems, 177P
CARRILLO, J. A. *see* BERTILSSON, L.
CARROLL, K. *see* PEARS, J. S.
CATTAN, D. *see* CHAPPEY, O.
CHADWICK, I. G. *see* ROWLAND, K.
CHAN, A. & YANG, J. M. The characterisation of sulphoxidation metabolites of moricizine using the isolated perfused rat liver, 167P
CHAPPEY, O., NEIL, E., DERVICHIAN, M., WAUTIER, J. L., SCHERRMANN, J. M. & CATTAN, D. Colchicine concentration in leukocytes of patients with familial Mediterranean fever, 87
CHARLES, B. G. *see* CHULAVATNATOL, S.
CHASLERIE, A. *see* BEGAUD, B.
CHEN, C. P. L.-H. *see* BOWMAN, A. J.
CHENERY, R. J. *see* BALDWIN, S. J.
CHENERY, R. J. *see* BLOOMER, J. C.
CHENERY, R. J. *see* CLARKE, S. E.
CHENERY, R. J. *see* LANKESTER, D. J.
CHIANG, C. P. *see* CHIANG, P. H.
CHIANG, P. H., WU, S. N., TSAI, E. M., WU, C. C., SHEN, M. R., HUANG, C. H. & CHIANG, C. P. Adenosine modulation of neurotransmission in penile erection, 357
CHIPMAN, J. K. *see* LANKESTER, D. J.
CHOONARA, I. *see* PARKER, A. C.
CHOWIENCZYK, P. J. *see* COCKCROFT, J. R.
CHRISTIANS, U. *see* BADER, A.
CHRISTIANS, U. *see* GONSCHIOR, A.-K.
CHULAVATNATOL, S. & CHARLES, B. G. Determination of dose-dependent absorption of amoxycillin from urinary excretion data in healthy subjects, 274
CLAPPERTON, M., MCMURRAY, J., FISHER, A. C. & DARGIE, H. J. The effect of angiotensin-converting enzyme inhibitors on human neutrophil chemotaxis *in vitro*, 53
CLARKE, S. E. *see* BALDWIN, S. J.
CLARKE, S. E. *see* BLOOMER, J. C.
CLARKE, S. E. *see* RASHIDI, M. R.
CLARKE, S. E., BALDWIN, S. J., BLOOMER, J. C., AYRTON, A. D. & CHENERY, R. J. Cytochrome P450 2E1 and lauric acid ω-1 hydroxylation in rat, dog and human liver microsomes, 174P
COCKCROFT, J. R., CHOWIENCZYK, P. J., BRETT, S. E. & RITTER, J. M. Effect of N^G-monomethyl-L-arginine on kinin-induced vasodilation in the human forearm, 307
COCKCROFT, J. R., CHOWIENCZYK, P. J., BRETT, S. E., BENDER, N. & RITTER, J. M. Inhibition of bradykinin-induced vasodilation in human forearm vasculature by icatibant, a potent β_2-receptor antagonist, 317
COHEN, C. *see* LAROCHE, F.
COLEMAN, R. *see* LANKESTER, D. J.
COLLIER, J. G. *see* O'KANE, K. P. J.
CONRAD, J. *see* SEIFERT, R. D.
CORNEL, M. C. *see* STURKENBOOM, M. C. J. M.
COSTAGLIOLA, D. *see* DIMIER-DAVID, L., COSTE, J., STRAUCH, G., LETRAIT, M. & BERTAGNA, X. Reliability of hormonal levels for assessing the hypothalamic-pituitary-adrenocortical system in clinical pharmacology, 474
COTREAU-BIBBO, M. M. *see* VON MOLTKE, L. L.
COUTIE, W. J. *see* CARGILL, R. I.
CRISCUOLI, M. *see* WYLD, P. J.
CROME, O. *see* BADER, A.
CROME, P. *see* BRUCE-JONES, P. N. E.
CRUL, B. J. P. *see* VAN DONGEN, R. T. M.
CURRIE, D. *see* MCDEVITT, D. G.
CUTLER, N. R. *see* SEIFERT, R. D.

D'ATHIS, Ph. *see* REY, E. A.
DAHL, M.-L. *see* BERTILSSON, L.
DARBY, Y. C. *see* SCADDING, G. K.
DARBYSHIRE, J. F. *see* GUILLOU, F.
DARGIE, H. J. *see* CLAPPERTON, M.
DATTA, S. *see* VAN DEN BERG, A. A.
DAVIS, J. D. *see* KHAN, A. Z.
DAVIS, J. D., BRENNAN, B., AARONS, L. & HOUSTON, J. B. Effect of norfloxacin on theophylline disposition: a comparison with other fluoroquinolones, 178P
DAVIS, T. M. E. *see* DYER, J. R.
DAY, R. Meeting report: Asian conference on clinical pharmacology and therapeutics, 197
DAY, R. O. *see* SEIDEMAN, P.
DAY, R. O. *see* WALKER, J. S.
DE JONG-VAN DEN BERG, L. T. W. *see* STURKENBOOM, M. C. J. M.
DE KEYSER, P. *see* HERMANS, L.
DE MEY, C., BREITHAUPT-GROGLER, K., SCHLOOS, J., PALM, D. & BELZ, G. G. Reproducibility and consistency of the responses to supine bicycle ergometry: evaluation in conjunction with β_1-adrenoceptor occupancies, 480
DE RONZAN, J. *see* KUHN, J. M.
DEBLANDER, A. *see* HERMANS, L.
DEL RE, G. *see* WYLD, P. J.
DELOMENIE, C., GRANT, D. M., MATHELIER-FUSADE, P., JACOMET, C., LEYNADIER, F., JACQZ-AIGRAIN, E., ROZENBAUM, W., KRISHNAMOORTHY, R. & DUPRET, J.-M. *N*-acetylation genotype and risk of severe reactions to sulphonamides in AIDS patients, 581
DERVICHIAN, M. *see* CHAPPEY, O.
DICKINS, M. *see* CARLILE, D. J.
DICKINSON, R. G. *see* BERNUS, I.
DIMIER-DAVID, L., BILLON, N., COSTAGLIOLA, D., JAILLON, P. & FUNCK-BRENTANO, C. Reproducibility of non-invasive measurement and of short-term variability of blood pressure and heart rate in healthy volunteers, 109
DITTERICH, W. *see* THÜRAUF, N.
DUBOIS, M. C. *see* REY, E. A.
DUNCAN, M. W. *see* SEIDEMAN, P.
DUPRET, J.-M. *see* DELOMENIE, C.
DYER, J. R., DAVIS, T. M. E., GIELE, C., ANNUS, T., GARCIA-WEBB, P. & ROBSON, J. The pharmacokinetics and pharmacodynamics of quinine in the diabetic and non-diabetic elderly, 205

EADIE, M. J. *see* BERNUS, I.
EAGLES, C. *see* HEAD, A.
EAP, C. B. *see* BAUMANN, P.
ECKERNÄS, S.-Å. *see* GRAHNEN, A.
EDWARDS, G. *see* GLAZIER, A. P.
EDWARDS, I. *see* WATTS, P.
EKINS, S., MURRAY, G. I., BURKE, M. D., MARCHANT, N. M. & HAWKSWORTH, G. M. Qualitative and quantitative comparison of testosterone hydroxylation and 7-ethoxy-coumarin-*O*-deethylation in Sprague Dawley rat hepatocytes and precision-cut liver slices, 164P
ELLIS, S. W. *see* ROWLAND, K.
ESSELMANN, H. *see* BADER, A.
EVANS, G. L., AYRTON, J. & WILSON, K. Calculation of *in vivo* clearance from *in vitro* data for a dihydropyridine calcium antagonist, lacidipine, 162P

FARR, S. J. *see* PARIKH, R.
FARRAR, G., MITCHELL, A. M., HOOPER, H., STEWART, F. & MALCOLM, S. L. Prediction of potential drug interactions of saquinavir (Ro 31-8959) from *in vitro* data, 162P
FISHER, A. C. *see* CLAPPERTON, M.
FORD, G. A. *see* BOWMAN, A. J.
FORESTER, E. R. *see* PARIKH, R.
FRANCIS, H. W. *see* OWEN, S. G.
FREESTONE, S. *see* LI KAM WA, T. C.
FRENCH-DUTCH FLUVASTATIN STUDY GROUP *see* JACOTOT, B.
FRÜHAUF, N. *see* BADER, A.
FUCHS, W., SENNEWALD, R. & KLOTA, U. Lansoprazole does not affect the bioavailability of oral contraceptives, 376
FUHR, U., STAIB, A. H., HARDER, S., BECKER, K., LIERMANN, D., SCHOLLNHAMMER, G. & ROED, I.-S. Absorption of ipsapirone along the human gastrointestinal tract, 83
FUNCK-BRENTANO, C. *see* DIMIER-DAVID, L.

GAMZU, E. *see* MUIR, K. W.
GARCIA-WEBB, P. *see* DYER, J. R.
GESCHER, A. *see* HARGREAVES, M. B.
GIELE, C. *see* DYER, J. R.
GIFFORD, L. A. *see* WITHEROW, L. E.
GLAZIER, A. P., KOKWARO, G. O., ISMAIL, S. & EDWARDS, G. Effect of an experimental malaria infection

on the metabolism of phenacetin in the rat isolated perfused liver, 167P
GOEHRS, M. *see* REY, E. A.
GONSCHIOR, A.-K., CHRISTIANS, U., BRAUN, F., WINKLER, M., LINCK, A., BAUMANN, J. & SEWING, K.-Fr. Measurement of blood concentrations of FK506 (tacrolimus) and its metabolites in seven liver graft patients after the first dose by h.p.l.c.-MS and microparticle enzyme immunoassay (MEIA), 567
GOUYET, L. *see* REY, E. A.
GRAHAM, G. G. *see* SEIDEMAN, P.
GRAHNEN, A., ECKERNÅS, S.-Å., BRUNDIN, R. M. & LING-ANDERSSON, A. An assessment of the systemic activity of single doses of inhaled fluticasone propionate in healthy volunteers, 521
GRANGER, N. *see* GRANT, M. H.
GRANT, D. M. *see* DELOMENIE, C.
GRANT, J. *see* WYLD, P. J.
GRANT, M. H. *see* WATTS, P.
GRANT, M. H., GRANGER, N. & MACDONALD, C. Comparative menadione toxicity in primary cultures and SV40-immortalised rat hepatocytes, 172P
GRANT, M. H., IRVINE, J., VASS, M. & MACDONALD, C. The effect of inducing agents on the xenobiotic metabolising enzyme activities of immortalised rat liver cells, 172P
GREENBLATT, D. J. *see* VON MOLTKE, L. L.
GROEN, K. *see* BURM, A. G. L.
GROSSET, D. G. *see* MUIR, K. W.
GROVE, A., ALLAM, A., MCFARLANE, L. C., MCPHATE, G., JACKSON, C. M. & LIPWORTH, B. J. A comparison of the systemic bioactivity of inhaled budesonide and fluticasone propionate in normal subjects, 527
GROVER, P. K. *see* PALIWAL, J. K.
GUILLOU, F., DARBYSHIRE, J. F. & CALDWELL, J. The enzymic basis for the regioselective *n*-alkyl hydroxylation of 6(*n*-propyl)-chromone-2-carboxylic acid (6nPCCA) in the rat, 159P
GUMBLETON, M., OIE, S. & VEROTTA, D. Pharmacokinetic-pharmacodynamic (PK-PD) modelling in non-steady-state studies and arterio-venous drug concentration differences, 389
GUPTA, R. C. *see* PALIWAL, J. K.

HAMBY, R. L. *see* HENDERSON, G. I.
HAMUNEN, K. *see* OLKKOLA, K. T.
HAQ, I. *see* ROWLAND, K.
HARAMBURU, F. *see* BEGAUD, B.
HARDER, S. *see* FUHR, U.
HARGREAVES, J. A., JEZEQUEL, S. & HOUSTON, J. B. Effect of azole antifungals on human microsomal metabolism of diclofenac and midazolam, 175P
HARGREAVES, M. B., GESCHER, A., JONES, B. C. & SMITH, D. A. Inhibition and induction of cytochrome P-4502E1 by a range of aromatic compounds, 158P
HARMATZ, J. S. *see* VON MOLTKE, L. L.
HARTMANN, A. *see* YEATES, R. A.
HATZINGER, M. *see* BAUMANN, P.
HAWKSWORTH, G. M. *see* EKINS, S.
HAWKSWORTH, G. M. *see* MORSMAN, J. M.
HE, G.-W., YANG, C.-Q., MACK, M. J., ACUFF, A. E. & RYAN, W. H. Interaction between endothelin and vasodilators in the human internal mammary artery, 505
HEAD, A., MAXWELL, S., KENDALL, M. J. & EAGLES, C. Exercise metabolism in healthy volunteers taking atenolol, high and low doses of metroprolol CR/Z0K, and placebo, 499
HEAF, D. *see* PARKER, A. C.
HEINE, P. R., WEYER, G., BREUEL, H.-P., MUCK, W., SCHMAGE, N. & KUHLMANN, J. Lack of interaction between diazepam and nimodipine during chronic oral administration to healthy elderly subjects, 39
HELSBY, N. A. *see* WRIGHT, J. D.
HEMMETER, U. *see* BAUMANN, P.
HENDERSON, G. I., PEREZ, A. B., YANG, Y., HAMBY, R. L., SCHENKEN, R. S. & SCHENKER, S. Transfer of dideoxyinosine across the human isolated placenta, 237
HERMANS, L., DEBLANDER, A., DE KEYSER, P., SCHEYS, I., LESAFFRE, E. & WESTELINCK, K. J. At equipotent doses, isradipine is better tolerated than amlodipine in patients with mild-to-moderate hypertension: a double-blind, randomized, parallel-group study, 335
HEWITT, P., BROCKLESBY, K. & HOTCHKISS, S. A. M. *In vitro*: *in vivo* correlations in human skin absorption of pharmaceutical agents, 163P
HIANG, T. C. *see* SENG, KHOO TAN, H.
HJEMDAHL, P. *see* WALLEN, N. H.
HOGGARD, P. G., VEAL, G. J., WILD, M. J. & BACK, D. J. Screening for drug interactions with zidovudine phosphorylation *in vitro*, 166P
HOLSBOER, E. *see* BAUMANN, P.
HONJOL, N. M. *see* VAN DEN BERG, A. A.
HOOPER, H. *see* FARRAR, G.
HOOPER, W. D. *see* BERNUS, I.
HOTCHKISS, S. A. M. *see* BROCKLESBY, K.
HOTCHKISS, S. A. M. *see* HEWITT, P.
HOUSTON, J. B. *see* CARLILE, D. J.
HOUSTON, J. B. *see* DAVIS, J. D.
HOUSTON, J. B. *see* HARGREAVES, J. A.
HOUSTON, J. B. *see* WITHEROW, L. E.
HOUSTON, J. B. *see* WORBOYS, P. D.
HOUSTON, J. B. *see* ZOMORODI, K.
HUANG, C. H. *see* CHIANG, P. H.
HYLAND, R. *see* JONES, B. C.

IDLE, J. R. *see* WALKER, D.
IRVINE, J. *see* GRANT, M. H.
ISIMER, A. *see* BASCI, N. E.
ISMAIL, S. *see* GLAZIER, A. P.
ITO, S. & KOREN, G. A novel index for expressing exposure of the infant to drugs in breast milk, 99

JACKSON, C. M. *see* GROVE, A.
JACKSON, P. R. *see* ROWLAND, K.
JACOMET, C. *see* DELOMENIE, C.
JACOTOT, B., BANGA, J. D., PFISTER, P., MEHRA, M. & FRENCH-DUTCH FLUVASTATIN STUDY GROUP. Efficacy of a low dose-range of fluvastatin (XU 62-320) in the treatment of primary hypercholesterolaemia. A dose-response study in 431 patients, 257
JACQZ-AIGRAIN, E. *see* DELOMENIE, C.
JACQZ-AIGRAIN, E., BESSA, E., MEDARD, Y., MIRCHEVA, Y. & VILMER, E. Thiopurine methyltransferase activity in a French population: h.p.l.c. assay conditions and effects of drugs and inhibitors, 1
JAEGER, R. *see* TROVIK, T. S.
JAILLON, P. *see* DIMIER-DAVID, L.
JAMIN, P. *see* LAROCHE, F.
JARMAN, M. *see* MALEY, M.
JAYAKODY, R. L. *see* WEERASURIYA, K.
JERLING, M., MERLE, Y., MENTRE, F. & MALLET, A. Population pharmacokinetics of nortriptyline during monotherapy and during concomitant treatment with drugs that inhibit CYP2D6—an evaluation with the nonparametric maximum likelihood method, 453
JEZEQUEL, S. *see* HARGREAVES, J. A.
JOHNSTON, N. R. *see* LI KAM WA, T. C.
JONES, B. C. *see* HARGREAVES, M. B.
JONES, B. C. *see* MORSMAN, J. M.
JONES, B. C., HYLAND, R., SMITH, D. A. & WALKER, D. K. Interaction of dofetilide with cytochrome P450 enzymes, 170P
JONKMAN, J. H. G. *see* STORM, G.
JORDE, R. *see* TROVIK, T. S.

KAHAN, A. *see* LAROCHE, F.
KALRA, L. *see* BRUCE-JONES, P. N. E.
KAMALI, F. *see* BALL, D. E.
KAMPF, G. & RITTER, J. M. Time-dependent inhibition by glyceryl trinitrate of platelet aggregation caused by U46619 (a thromboxane/endoperoxide receptor agonist), 80
KARBWANG, J. *see* NA-BANGCHANG, K.
KAUL, S. *see* SEIFERT, R. D.
KAYAALP, S. O. *see* BASCI, N. E.
KEIDAR, S., AVIRAM, M., MAOR, I., OIKNINE, J. & BROOK, J. G. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor

activity in macrophages: *in vitro* and *in vivo* studies, 513
KENDALL, M. J. *see* HEAD, A.
KERRY, N. L., SOMOGYI, A. A., BOCHNER, F. & MIKUS, G. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: *in vitro* studies using human liver microsomes, 243
KHAN, A. Z., DAVIS, J. D., TOON, S., LANGLEY, S., MUNAFO, A., PORCHET, H. & LE COTONNEC, J.-Y. A study investigating the pharmacokinetic and pharmacodynamic equivalence of two recombinant-human growth hormone formulations administered subcutaneously, 177P
KITTERINGHAM, N. R. *see* PARKER, A. C.
KLOTA, U. *see* FUCHS, W.
KLOTZ, U. *see* SCHOLZ, J.
KOBAL, G. *see* THÜRAUF, N.
KOBAYASHI, T. *see* MIZUTANI, N.
KOKWARO, G. O. *see* GLAZIER, A. P.
KOOPMAN-KIMENAI, P. M. *see* VAN DONGEN, R. T. M.
KOOPMANS, P. P. *see* VAN DER VEN, A. J. A. M.
KOREN, G. *see* ITO, S.
KRISHNA, D. R. *see* SCHOLZ, J.
KRISHNAMOORTHY, R. *see* DELOMENIE, C.
KUHLMANN, J. *see* HEINE, P. R.
KUHN, J. M., LEGRAND, A., RUIZ, J. M., OBACH, R., DE RONZAN, J. & THOMAS, F. Pharmacokinetic and pharmacodynamic properties of a long-acting formulation of the new somatostatin analogue, lanreotide, in normal healthy volunteers, 213

LANGLEY, S. *see* KHAN, A. Z.
LANKESTER, D. J., CHIPMAN, J. K., COLEMAN, R. & CHENERY, R. J. Modelling of biliary excretion by metabolism and accumulation studies in hepatocyte couplets, 170P
LAROCHE, F., KAHAN, A., KAHAN, A., LETRAIT, M. COHEN, C., JAMIN, P. & STRAUCH, G. Ketoprofen and prednisolone do not modulate neutrophil CR1, CR3 and Fc RIII expression in healthy volunteers, 441
LASSALE, C. *see* REY, E. A.
LE COTONNEC, J.-Y. *see* KHAN, A. Z.
LEE, M. R. *see* LI KAM WA, T. C.
LEES, K. R. *see* MACFADYEN, R. J.
LEES, K. R. *see* MUIR, K. W.
LEES, K. R. *see* SQUIRE, I. B.
LEGRAND, A. *see* KUHN, J. M.
LENNARD, M. S. *see* ROWLAND, K.
LENNARD, M. S. *see* WEERASURIYA, K.
LESAFFRE, E. *see* HERMANS, L.
LETRAIT, M. *see* COSTE, J.
LETRAIT, M. *see* LAROCHE, F.
LEYNADIER, F. *see* DELOMENIE, C.
LI KAM WA, T. C., FREESTONE, S., SAMSON, R. R., JOHNSTON, N. R. & LEE, M. R. The antinatriuretic action of γ-glutamyl-5-hydroxy-L-tryptophan is dependent on its decarboxylation to 5-hydroxy-tryptamine in normal man, 265
LIERMANN, D. *see* FUHR, U.
LIMPAIBUL, L. *see* NA-BANGCHANG, K.
LINCK, A. *see* GONSCHIOR, A.-K.
LINDSTROM, L. *see* BEERTILSSON, L.
LING-ANDERSON, A. *see* GRAHNEN, A.
LIPPI, A. *see* WYLD, P. J.
LIPWORTH, B. J. *see* CARGILL, R. I.
LIPWORTH, B. J. *see* GROVE, A.
LIPWORTH, B. J. *see* WHEELDON, N. M.
LLERENA, A. *see* BERTILSSON, L.
LOHRER, F. *see* SEIDEMAN, P.
LUURILA, H. *see* ARANKO, K.
LYONS, D., STEWART, D., WEBSTER, J. & BENJAMIN, N. Angiotensin converting enzyme inhibition does not affect the response to exogenous angiotensin II in the human forearm, 417

MACDONALD, C. *see* GRANT, M. H.
MACFADYEN, R. J. *see* SQUIRE, I. B.
MACFADYEN, R. J., LEES, K. R. & REID, J. L. Responses to low dose intravenous perindoprilat infusion in salt deplete/salt replete normotensive volunteers, 329
MACK, M. J. *see* HE, G.-W.
MACRAE, P. V. *see* BEAUMONT, K. C.
MADDEN, S. *see* SPALDIN, V.
MALCOLM, S. L. *see* FARRAR, G.
MALEY, M., WEAVER, R. J., JARMAN, M. & BURKE, M. D. Comparison of tamoxifen and idoxifene metabolism by human liver microsomal cytochromes P450, 165P
MALLET, A. *see* JERLING, M.
MANTEL, M. A. *see* VAN DER VEN, A. J. A. M.
MAOR, I. *see* KEIDAR, S.
MARCHANT, N. M. *see* EKINS, S.
MATHELIER-FUSADE, P. *see* DELOMENIE, C.
MATTHEW, D. E. *see* MCLACHLAN, A. J.
MAUNUKSELA, E.-L. *see* OLKKOLA, K. T.
MAXWELL, S. *see* HEAD, A.
MCDEVITT, D. G. *see* WHEELDON, N. M.
MCDEVITT, D. G., CURRIE, D., NICHOLSON, A. N., WRIGHT, N. A. & ZETLEIN, M. B. Central effects of the diuretic bendrofluazide, 249
MCFARLANE, L. C. *see* GROVE, A.
MCLACHLAN, A. J., MATTHEW, D. E. & ROWLAND, M. Application of a semi-parametric physiologic model to cyclosporin tissue distribution in the rat, 156P
MCLAUGHLIN, W. S. *see* BALL, D. E.
MCMURRAY, J. *see* CLAPPERTON, M.
MCPHATE, G. *see* GROVE, A.
MEDARD, Y. *see* JACQZ-AIGRAIN, E.
MEDICINES CONTROL AGENCY, COMMITTEE ON SAFETY OF. Guidelines for company-sponsored Safety Assessment of Marketed Medicines (SAMM guidelines), 95
MEHRA, M. *see* JACOTOT, B.
MENTRE, F. *see* JERLING, M.
MERLE, Y. *see* JERLING, M.
MIKUS, G. *see* KERRY, N. L.
MILLER, C. M. *see* BEAUMONT, K. C.
MILLSON, D. S. *see* PEARS, J. S.
MINERS, J. O. *see* ANDERSSON, T.
MIRCHEVA, Y. *see* JACQZ-AIGRAIN, E.
MITCHELL, A. M. *see* FARRAR, G.
MIZUTANI, N., KOBAYASHI, T. & WATANABE, T. Preliminary study of the efficacy of xamoterol in bradycardia-tachycardia syndrome, 285
MORIDE, Y. *see* BEGAUD, B.
MORSMAN, J. M., SMITH, D. A., JONES, B. C. & HAWKSWORTH, G. M. Investigation of substrate structure-activity relationships for CYP2C9 using phenytoin and bis-triazole antifungal analogues, 156P
MUCK, W. *see* HEINE, P. R.
MUIR, K. W., GROSSET, D. G., GAMZU, E. & LEES, K. R. Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers, 33
MUNAFO, A. *see* KHAN, A. Z.
MURALEEDARAN, R. *see* VAN DEN BERG, A. A.
MURAT, I. *see* REY, E. A.
MURRAY, G. I. *see* EKINS, S.

NA-BANGCHANG, K., LIMPAIBUL, L., THANAVIBUL, A., TAN-ARIYA, P. & KARBWANG, J. The pharmacokinetics of chloroquine in healthy Thai subjects and patients with *Plasmodium vivax* malaria, 278
NEIL, E. *see* CHAPPEY, O.
NEUVONEN, P. J. *see* ARANKO, K.
NGUYEN, T. V. *see* WALKER, J. S.
NICHOLSON, A. N. *see* MCDEVITT, D. G.
NITYANAND, S. *see* PALIWAL, J. K.

O'KANE, K. P. J., WEBB, D. J., COLLIER, J. G. & VALLANCE, P. J. T. Local L-N^G-monomethyl-arginine attenuates the vasodilator action of bradykinin in the human forearm, 311
OBACH, R. *see* KUHN, J. M.
OIE, S. *see* GUMBLETON, M.
OIKNINE, J. *see* KEIDAR, S.
OLIVER, G. *see* REY, E. A.
OLKKOLA, K. T. *see* ARANKO, K.
OLKKOLA, K. T., HAMUNEN, K., SEPPALA, T. & MAUNUKSELA, E.-L. Pharmacokinetics and ventilatory effects of intravenous oxycodone in postoperative children, 71
OOSTERHUIS, B. *see* STORM, G.
OWEN, S. G., FRANCIS, H. W. & ROBERTS, M. S. Disappearance kinetics of solutes from synovial fluid after intra-articular injection, 349

PALIWAL, J. K., GROVER, P. K., ASTHANA, O. P., NITYANAND, S. & GUPTA, R. C. Excretion of centchroman in breast milk, 485
PALM, D. *see* DE MEY, C.
PARIKH, R., SWEETLAND, J., FORSTER, E. R., BEDDING, A. W., FARR, S. J. & SMITH, J. T. L. Ranitidine bismuth citrate and ranitidine do not affect gastric emptying of a radiolabelled meal, 577
PARIENTE-KHAYAT, A. *see* REY, E. A.
PARK, B. K. *see* SPALDIN, V.
PARKER, A. C., PRESTON, T., HEAF, D., KITTERINGHAM, N. R. & CHOONARA, I. Inhibition of caffeine metabolism by ciprofloxacin in children with cystic fibrosis as measured by the caffeine breath test, 573
PEARS, J. S., TUERSLEY, M. D., CARROLL, K., WEBB, W., RUANE, R. J., MILLSON, D. S. & WILLIAMS, A. J. Tolerance and pharmacokinetics of single oral doses of a novel β_3-adrenoceptor agonist, ZD2079, in healthy male volunteers, 161P
PEREZ, A. B. *see* HENDERSON, G. I.
PFAFF, G. *see* YEATES, R. A.
PFISTER, P. *see* JACOTOT, B.
PIPER, P. J. *see* BARKER, J. E.
POHL, S. *see* SCHOLZ, J.
PONS, G. *see* REY, E. A.
POOL, W. F. *see* SPALDIN, V.
PORCHET, H. *see* KHAN, A. Z.
PRESTON, T. *see* PARKER, A. C.

RAMA PRABHU, N. V. *see* VAN DEN BERG, A. A.
RAMOS, S. *see* BERTILSSON, L.
RAMSAY, L. E. *see* ROWLAND, K.
RANU, H. K. *see* WALKER, D.
RASHIDI, M. R., SMITH, J. A., CLARKE, S. E. & BEEDHAM, C. Involvement of rat and guinea pig aldehyde oxidase in the *in vitro* conversion of famciclovir to penciclovir, 160P
RAWLINS, M. D. *see* WALLER, P. C.
REID, J. L. *see* MACFADYEN, R. J.
REID, J. L. *see* SQUIRE, I. B.
REY, E. A., PARIENTE-KHAYAT, A., GOUYET, L., VAUZELLE-KERVROEDAN, F., PONS, G., D'ATHIS, Ph., DUBOIS, M. C., MURAT, I., LASSALE, C., GOEHRS, M., SAINT-MAURICE, C. L. & OLIVER, G. Stereoselective disposition of ibuprofen enantiomers in infants, 373
RITTER, J. M. *see* KAMPF, G.
RITTER, J. M. *see* COCKCROFT, J. R.
ROBERTS, M. S. *see* OWEN, S. G.
ROBERTS, S. J. & BATEMAN, D. N. The use of nitrates, calcium channel blockers and ACE inhibitors in primary care in the Northern Region: a pharmacoepidemiological study, 489
ROBSON, J. *see* DYER, J. R.
RODRIGUEZ DE LA RUBIA, I. *see* BERTILSSON, L.
ROED, I.-S. *see* FUHR, U.
ROTHERHAM, N. E. *see* BYROM, W. D.
ROWLAND, K., ELLIS, S. W., LENNARD, M. S. & TUCKER, G. T. Characterisation of the enantioselective metabolism of metoprolol by CYP2D6 expressed in yeast, 165P
ROWLAND, K., YEO, W. W., ELLIS, S. W., CHADWICK, I. G., HAQ, I., LENNARD, M. S., JACKSON, P. R., RAMSAY, L. E. & TUCKER, G. T. Inhibition of CYP2D6 activity by treatment with propranolol and the role of 4-hydroxy propranolol, 9
ROWLAND, M. *see* MCLACHLAN, A. J.
ROZARIO, C. J. *see* VAN DEN BERG, A. A.
ROZENBAUM, W. *see* DELOMENIE, C.
RUANE, R. J. *see* PEARS, J. S.
RUHNKE, M. *see* YEATES, R. A.
RUIZ, J. M. *see* KUHN, J. M.
RYAN, W. H. *see* HE, G.-W.

SAGER, G. *see* TROVIK, T. S.
SAINT-MAURICE, C. L. *see* REY, E. A.
SAMSON, R. R. *see* LI KAM WA, T. C.
SARNOW, E. *see* YEATES, R. A.
SAVVA, D. *see* VAN DEN BERG, A. A.
SAYAL, A. *see* BASCI, N. E.
SCADDING, G. K., DARBY, Y. C. & AUSTIN, C. E. Effect of short-term treatment with fluticasone propionate nasal spray on the response to nasal allergen challenge, 447
SCHENKEN, R. S. *see* HENDERSON, G. I.
SCHENKER, S. *see* HENDERSON, G. I.
SCHERRMANN, J. M. *see* CHAPPEY, O.
SCHEYS, I. *see* HERMANS, L.
SCHLOOS, J. *see* DE MEY, C.
SCHMAGE, N. *see* HEINE, P. R.
SCHOLLNHAMMER, G. *see* FUHR, U.
SCHOLZ, J., BAUSE, H., SCHULZ, M., KLOTZ, U., KRISHNA, D. R., POHL, S. & SCHULTE AM ESCH, J. Pharmacokinetics and effects on intracranial pressure of sufentanil in head trauma patients, 369
SCHULTE AM ESCH, J. *see* SCHOLZ, J.
SCHULZ, M. *see* SCHOLZ, J.
SEIDEMAN, P., LOHRER, F., GRAHAM, G. G., DUNCAN, M. W., WILLIAMS, K. M. & DAY, R. O. The stereoselective disposition of the enantiomers of ibuprofen in blood, blister and synovial fluid, 221
SEIFERT, R. D., STEWART, M. B., SRAMEK, J. J., CONRAD, J., KAUL, S. & CUTLER, N. R. Pharmacokinetics of co-administered didanosine and stavudine in HIV-seropositive male patients, 405
SEIFRITZ, E. *see* BAUMANN, P.
SENG, KHOO TAN H., THONG, C. E. & HIANG, T. C. Anti-emetic effect of high-dose metoclopramide *vs* alizapride—a randomised crossover study, 282
SENNEWALD, R. *see* FUCHS, W.
SEPPALA, T. *see* OLKKOLA, K. T.
SEWING, K.-Fr. *see* BADER, A.
SEWING, K.-Fr. *see* GONSCHIOR, A.-K.
SEYMOUR, R. A. *see* BALL, D. E.
SHADER, R. I. *see* VON MOLTKE, L. L.
SHEN, M. R. *see* CHIANG, P. H.
SKETT, P. *see* WOODE, E.
SMITH, C. A. D. *see* WEERASURIYA, K.
SMITH, D. A. *see* BEAUMONT, K. C.
SMITH, D. A. *see* HARGREAVES, M. B.
SMITH, D. A. *see* JONES, B. C.
SMITH, D. A. *see* MORSMAN, J. M.
SMITH, G. J. *see* BALDWIN, S. J.
SMITH, G. J. *see* BLOOMER, J. C.
SMITH, J. A. *see* RASHIDI, M. R.
SMITH, J. T. L. *see* PARIKH, R.
SMITH, M. D. *see* WATTS, P.
SOLLIE, F. A. E. *see* STORM, G.
SOMMER, W. *see* STORM, G.
SOMOGYI, A. A. *see* KERRY, N. L.
SPALDIN, V., MADDEN, S., POOL, W. F., WOOLF, T. F. & PARK, B. K. The effect of enzyme inhibitor on the metabolism and activation of tacrine by human liver microsomes, 15
SQUIRE, I. B., MACFADYEN, R. J., LEES, K. R., STEWART-HILLIS, W. & REID, J. L. Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure, 117
SRAMEK, J. J. *see* SEIFERT, R. D.
STAIB, A. H. *see* FUHR, U.
STEWART, D. *see* LYONS, D.
STEWART, F. *see* FARRAR, G.
STEWART, M. B. *see* SEIFERT, R. D.
STEWART-HILLIS, W. *see* SQUIRE, I. B.
STORM, G., OOSTERHUIS, B., SOLLIE, F. A. E., VISSCHER, H. W., SOMMER, W., BEITINGER, H. & JONKMAN, J. H. G. Lack of pharmacokinetic interaction between vinpocetine and oxazepam, 143
STRAUCH, G. *see* COSTE, J.
STRAUCH, G. *see* LAROCHE, F.
STRIBBLING, S. M. & CALDWELL, J. Comparative elimination of allyl isothiocyanate (AITC) in rats and mice, 159P
STRICKER, B. H. C. H. *see* STURKENBOOM, M. C. J. M.
STURKENBOOM, M. C. J. M., DE JONG-VAN DEN BERG, L. T. W., VAN VOORST-VADER, P. C., CORNEL, M. C., STRICKER, B. H. C. H. & WESSELING, H. Inability to detect plasma etretinate and acitretin is a poor predictor of the absence of these teratogens in tissue after stopping acitretin treatment, 229
SUBISSI, A. *see* WYLD, P. J.
SWEETLAND, J. *see* PARIKH, R.

TAN-ARIYA, P. *see* NA-BANGCHANG, K.
THANAVIBUL, A. *see* NA-BANGCHANG, K.
THOMAS, F. *see* KUHN, J. M.
THONG, C. E. *see* SENG, KHOO TAN H.

THÜRAUF, N., DITTERICH, W. & KOBAL, G. Different sensitivity of pain-related chemosensory potentials evoked by stimulation with CO_2, tooth pulp event-related potentials, and acoustic event-related potentials to the tranquilizer diazepam, 545
TOON, S. *see* KHAN, A. Z.
TRAUTMANN, M. *see* YEATES, R. A.
TREASURE, T. *see* BARKER, J. E.
TROVIK, T. S., JAEGER, R., JORDE, R. & SAGER, G. Reduced sensitivity to β-adrenoceptor stimulation and blockade in insulin dependent diabetic patients with hypoglycaemia unawareness, 427
TSAI, E. M. *see* CHIANG, P. H.
TUBERT-BITTER, P. *see* BEGAUD, B.
TUCKER, G. T. *see* ROWLAND, K.
TUCKER, G. T. *see* WEERASURIYA, K.
TUERSLEY, M. D. *see* PEARS, J. S.

VALLANCE, P. J. T. *see* O'KANE, K. P. J.
VAN DEN BERG, A. A., HONJOL, N. M., RAMA PRABHU, N. V., DATTA, S., ROZARIO, C. J., MURALEEDARAN, R. & SAVVA, D. Analgesics and ENT surgery, 533
VAN DER MEER, A. D. *see* BURM, A. G. L.
VAN DER MEER, J. W. M. *see* VAN DER VEN, A. J. A. M.
VAN DER VEN, A. J. A. M., MANTEL, M. A., VREE, T. B., KOOPMANS, P. P. & VAN DER MEER, J. W. M. Formation and elimination of sulphamethoxazole hydroxylamine after oral administration of sulphamethoxazole, 147
VAN DONGEN, R. T. M., CRUL, B. J. P., KOOPMAN-KIMENAI, P. M. & VREE, T. B. Morphine and morphine-glucuronide concentrations in plasma and CSF during long-term administration of oral morphine, 271
VAN KLEEF, J. W. *see* BURM, A. G. L.
VAN VOORST-VADER, P. C. *see* STURKENBOOM, M. C. J. M.
VASS, M. *see* GRANT, M. H.
VAUZELLE-KERVROEDAN, F. *see* REY, E. A.
VEAL, G. J. *see* HOGGARD, P. G.
VEAL, G. J., WILD, M. J., BARRY, M. G. & BACK, D. J. Effects of dideoxyinosine and dideoxycytidine on the intracellular phosphorylation of zidovudine in human mononuclear cells, 323
VERONESE, M. E. *see* ANDERSSON, T.
VEROTTA, D. *see* GUMBLETON, M.
VILMER, E. *see* JACQZ-AIGRAIN, E.
VISSCHER, H. W. *see* STORM, G.
VON MOLTKE, L. L., GREENBLATT, D. J., COTREAU-BIBBO, M. M., HARMATZ, J. S. & SHADER, R. I. Inhibitors of alprazolam metabolism *in vitro*; effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidine, 23
VREE, T. B. *see* VAN DER VEN, A. J. A. M.
VREE, T. B. *see* VAN DONGEN, R. T. M.

WALKER, D., RANU, H. K. & IDLE, J. R. Discovery, characterisation and importance of a novel metabolic pathway of ifosfamide, 157P
WALKER, D. K. *see* JONES, B. C.
WALKER, J. S., NGUYEN, T. V. & DAY, R. O. Clinical response to non-steroidal anti-inflammatory drugs in urate-crystal induced inflammation: a simultaneous study of intersubject and intrasubject variability, 341
WALLEN, N. H., ANDERSSON, A. & HJEMDAHL, P. Effects of treatments with oral isosorbide dinitrate on platelet function *in vitro*: a double-blind placebo-controlled study in patients with stable angina pectoris, 63
WALLER, P. C., WOOD, S. M., BRECKENRIDGE, A. M. & RAWLINS, M. D. Why the Safety Assessment of Marketed Medicines (SAMM) guidelines are needed, 93
WARD, S. A. *see* WRIGHT, J. D.
WATANABE, T. *see* MIZUTANI, N.
WATTS, P., SMITH, M. D., ZAMMITT, V., EDWARDS, I., BROWN, V. & GRANT, M. H. Comparison of the effect of medium composition on cytochrome P450 and glutathione content and urea synthesis in primary cultures of rat and sheep hepatocytes, 171P
WAUTIER, J. L. *see* CHAPPEY, O.
WEAVER, R. J. *see* MALEY, M.
WEBB, D. J. *see* O'KANE, K. P. J.
WEBB, W. *see* PEARS, J. S.
WEBSTER, J. *see* LYONS, D.
WEERASURIYA, K., JAYAKODY, R. L., SMITH, C. A. D., WOLF, C. R., TUCKER, G. T. & LENNARD, M. S. Debrisoquine and mephenytoin oxidation in Sinhalese: a population study, 466
WESSELING, H. *see* STURKENBOOM, M. C. J. M.
WESTERLINCK, K. J. *see* HERMANS, L.
WEYER, G. *see* HEINE, P. R.
WHEELDON, N. M., MCDEVITT, D. G. & LIPWORTH, B. J. The effects of lower than conventional doses of oral nadolol on relative β_1/β_2-adrenoceptor blockade, 103
WILD, M. J. *see* HOGGARD, P. G.
WILD, M. J. *see* VEAL, G. J.
WILLIAMS, A. J. *see* PEARS, J. S.
WILLIAMS, K. M. *see* SEIDEMAN, P.
WILSON, K. *see* EVANS, G. L.
WINKLER, M. *see* GONSCHIOR, A.-K.
WITHEROW, L. E., GIFFORD, L. A. & HOUSTON, J. B. Kinetics of phenytoin metabolism by rat hepatic microsomes in a two-compartment incubation system, 168P
WOLF, C. R. *see* WEERASURIYA, K.
WOOD, S. M. *see* WALLER, P. C.
WOODE, E. & SKETT, P. No evidence for dimethyl sulphoxide arresting reciprocal changes in adrenergic responses in hepatocytes, 161P
WOOLF, T. F. *see* SPALDIN, V.
WORBOYS, P. D., BRADBURY, A. & HOUSTON, J. B. Ethoxycoumarin *O*-deethylase activity in precision cut rat liver slices, 176P
WRIGHT, J. D., HELSBY, N. A. & WARD, S. A. The *in vitro* metabolism of proguanil: a role of CYP3A?, 169P
WRIGHT, N. A. *see* MCDEVITT, D. G.
WRIGHT, P. A. *see* BEAUMONT, K. C.
WU, C. C. *see* CHIANG, P. H.
WU, S. *see* CHIANG, P. H.
WYLD, P. J., GRANT, J., LIPPI, A., CRISCUOLI, M., DEL RE, G. & SUBISSI, A. Pharmacokinetics and biochemical efficacy of idrapril calcium, a novel ACE inhibitor , after multiple oral administration in humans, 421

YANG, C.-Q. *see* HE, G.-W.
YANG, J. M. *see* CHAN, A.
YANG, Y. *see* HENDERSON, G. I.
YEATES, R. A., RUHNKE, M., PFAFF, G., HARTMANN, A., TRAUTMANN, M. & SARNOW, E. The pharmacokinetics of fluconazole after a single intravenous dose in AIDS patients, 77
YELLON, D. M. *see* BAXTER, G. F.
YEO, W. W. *see* ROWLAND, K.

ZAMMITT, V. *see* WATTS, P.
ZEIJLMANS, P. W. M. *see* BURM, A. G. L.
ZETLEIN, M. B. *see* MCDEVITT, D. G.
ZOMORODI, K. & HOUSTON, J. B. Selective inhibition of diazepam metabolism by omeprazole in human liver microsomes, 175P

SUBJECT INDEX

This index was compiled from the keywords

(P = Proceedings)

ACE inhibition, 421
ACE inhibitor, 53, 117, 489
AIDS, 77
AIDS patients, 579
Absorption, 83, 164P, 274
Acitretin, 229
Adenosine, 357
Adenosine receptor, 357
Adverse drug reactions, 401
Aggregation, 80
Albumin efflux, 349
Aldehyde oxidase, 160P
Aldosterone, 265
Alizapride, 282
Allergen challenge, 447
Allyl isothiocyanate, 159P
Alprazolam, 23
Amesergide, 151
Amlodipine, 335
Amoxycillin, 274
Analgesics, 533
Angiotensin II, 57, 139, 417
Ankle oedema, 335
Antagonism, 480
Anti-cancer drug, 157P
Anti-emesis, 282
Antihypertensive, 335
Antimycotic drugs, 77
Arterio-venous difference, 389
Asthma, 527
Atenolol, 499
Azapirones, 83
Azole antifungals, 175P

β-adrenergic sensitivity, 427
β-adrenoceptor, 103, 480
β_3-adrenoceptor antagonist, 161P
β-adrenoceptor blockade, 499
β-adrenoceptor blocker, 199
β-adrenoceptor partial agonist, 285
β_2-receptors, 63
β-thromboglobulin, 317
BTS 67 582, 249, 433
Bendrofluazide, 249
Benzodiazepine, 39, 545
Bicycle ergometry, 480
Biliary excretion, 170P
Bioactivation, 15
Bis-triazole antifungal analogues, 156P
Blood pressure, 109, 117, 329
Bound drug transport, 349
Bradycardia-tachycardia syndrome, 285
Bradykinin, 307, 317
Breast milk, 485
Breast-feding, 99
Budesonide, 527
Bupivacaine enantiomers, 125
Buprenorphine, 533

CNS 1102, 33
CNS effects, 249
CR/Z0K, 499
CYP isoforms, 131
CYP1A2, 15, 471
CYP2C9, 156P
CYP2D6, 9, 165P, 243, 453
CYP3A, 169P, 557
Caffeine, 471
Caffeine breath test, 577
Calcium channel blocker, 489
Cancer pain, 271
Captopril, 53
Carbidopa, 265
Cardiac arrhythmia, 167P
Cardioprotection, 381
Carvedilol, 480
Celiprolol, 480
Centchroman, 485
Chemotaxis, 53
Children, 577
Chloroquine, 278
Cholesterol, 513
Ciprofloxacin, 597
Cisplatin, 282
Clearance, 99
Clozapine, 471
Cognitive function, 45
Colchicine, 87
Colour duplex sonography, 357
Coronary artery disease, 257
Corticosteroid, 527
Crystal-induced inflammation, 341
Cyclosporin, 156P
Cystic fibrosis, 165P, 170P, 171P
Cytochrome P 450, 577
Cytochrome P-450 2E1, 158P, 174P
Cytochrome P450 2C9, 174P
Cytochrome P450-3A, 23

ddI, 23
Debrisoquine, 237, 463, 466
O-demethylation, 243
Depression, 151
Desmethylsertraline, 23
Dextromethorphan, 151, 243
Diazepam, 39, 131, 175P, 545
Diclofenac, 175P, 533
Didanosine, 405
Dideoxyinosine, 237
Dihydropyridine, 39
Dihydropyridine calcium antagonist, 162P
Dimethyl sulphoxide, 161P
Diuretic, 249
Diurnal variation, 143
Dofetilide, 170P
Dose-dependent, 274
Drug, 99
Drug biotransformation, 158P
Drug delivery device, 83
Drug interactions, 39, 323, 376, 453
Drug metabolism, 177P, 567
Drug–drug interaction, 405

Ear anaesthesia, 533
Effects on performance, 39
Elderly, 205
Elderly healthy volunteers, 39
Electroencephalogram, 545
E_{max} model, 433
Enalapril, 417
Enalaprilat, 53
Enantiomers, 221, 373
Enantioselective metabolism, 165P
Endothelin, 505
Endothelium, 57, 199, 307, 311
Enzyme activities, 172P
Enzyme induction, 158P
Enzyme inhibition, 158P
Equivalence, 177P
Erythromycin, 363
Ethnic differences, 466
Ethoxycourmarin *O*-deethylase, 176P
7-ethoxycoumarin-*O*-deethylation, 164P
Etretinate, 229
Event-related potential, 545
Exercise, 480
Extensive metaboliser, 243

FK506, 567
FK506 metabolites, 567
Famciclovir, 160P
Familial Mediterranean fever, 87
Fat oxidation, 499
Fatigue, 499
Fentanyl, 533
Filtragometry, 63
Fluconazole, 77
Fluoroquinolones, 178P
Fluoxetine, 23
Fluticasone propionate, 447, 521, 527
Fluvastatin, 257
Forearm blood flow, 311, 317, 411

Gamma-L-glutamyl-5-hydroxy-L-tryptophan, 265
Gamma scintigraphy, 577
Gastric emptying, 577
Genetic polymorphism, 1, 463
Gingival overgrowth, 168P
Glucosidation, 411
Glutathione, 171P
Glyceryl trinitrate, 80, 311, 505
Granisetron, 173P, 557
Granulocytes, 87

HF-capsule, 83
HIV, 405
HMG-CoA reductase inhibitor, 257
Human saphenous vein, 57
Heart failure, 117, 489
Heart rate, 109
Hepatocyte couplets, 170P
Hepatocytes, 158P, 161P, 164P, 171P, 172P

High dose metoclopramide, 282
Histamine, 447
Hormonal levels, 474
Hormones, 376
H.p.l.c.–MS, 567
Human forearm vasculature, 307
Human gastrointestinal tract, 83
Human liver microsomes, 243, 557
Human microsomes, 131
Human milk, 99
Human volunteers, 421
Hydrocortisone, 164P
5-hydroxytryptamine, 265
Hypercholesterolaemia, 257
Hypertension, 489
Hypoglycaemia unawareness, 427
Hysteresis, 389, 433

IDDM, 427
Ibuprofen, 221, 341
Icatibant, 317
Idoxifene, 165P
Idrapril calcium, 421
Ifosfamide, 157P
Impotence, 357
In vitro metabolism, 23
In-patient anaesthesia, 533
Indomethacin, 45
Inducing agents, 172P
Induction, 376
Infant, 00
Infants, 373
Inhibition, 15, 376, 411
Interaction, 143, 162P, 166P, 363, 411
Internal mammary artery coronary bypass, 505
Internal thoracic artery, 57
Intracellular phosphorylation, 323
Intracranial pressure, 369
Intraoperative analgesia, 533
Intravenous ACE inhibition, 329
Ipsapirone, 83
Irreversible binding, 9
Ischaemia, 381
Ischaemic heart disease, 63, 489
Ischaemic preconditioning, 381
Isoprenaline sensitivity test, 427
Isosorbide dinitrate, 63
Isradipine, 335

Ketoconazole, 23
Ketoprofen, 441
Kidney, 265
Kinetics, 131
Kinetics ibuprofen, 373

L-NMMA, 311
LDL-receptor, 513
LTC_4, 447
Lacidipine, 162P
Lanreotide, 213
Lansoprazole, 376
Lauric acid ω-1 hydroxylation, 174P
Liquid meal, 577
Lipoproteins, 257
Liver microsomes, 165P, 174P
Liver slices, 164P, 176P

Macrophages, 513
Malaria, 167P, 278
Man, 317, 417, 577
Meeting report, 197
Menadione, 172P
Mephenytoin, 463
Metabolism, 164P, 513
Method, 109
Metoprolol, 165P, 480, 499
Metoprolol sensitivity test, 427
Michaelis-Menten, 274
Microsomal metabolism, 175P
Microsomes, 173P
Midazolam, 175P, 369
Modelling, 389
Monitoring, 229
Monocytes, 513
Mononuclear cells, 87
Moricizine, 167P
Morphine, 533
Morphine glucuronides, 271

N-acetylation genotype, 579
N-demethylation, 243
N-methyl D-aspartate (NMDA), 33
N^G-monomethyl-L-arginine, 307
Nadolol, 103
Nalbuphine, 533
Nasal, 447
Natriuretic peptides, 139
Nebivolol, 199
Neuroprotection, 33
Neutrophil receptors, 441
Neutrophils, 53
Nifedipine, 505
Nimodipine, 39
Nitrate, 489
Nitric oxide, 80, 199, 307, 311
Nitric oxide synthase, 311
Non-competitive antagonists, 33
Non-insulin dependent diabetes mellitus, 205
Non-steroidal anti-inflammatory drugs, 341
Nonparametric maximum likelihood, 453
Norfloxacin, 178P
Norfluoxetine, 23
Normal men, 213
Nose anaesthesia, 533
Nortriptyline, 453

Omeprazole, 175P
Opioid, 369
Oral contraceptives, 376, 485
Oral hypoglycaemic, 433
Oral morphine, 271
Oxazepam, 143
Oxycodone, 71

PGD_2, 447
Pain measurement, 545
Penciclovir, 160P
Performance, 249
Perindoprilat, 329
Pethidine, 533
Pharmacodynamic variability, 341
Pharmacodynamics, 39, 177P, 181, 205, 213, 389, 433
Pharmacokinetic-dynamic models, 71
Pharmacokinetics, 39, 71, 77, 125, 161P, 168P, 177P, 179P, 205, 213, 274, 278, 363, 369, 389, 405, 421, 433, 505, 567
Pharmacology, 289
Pharmacovigilance, 401
Phenacetin, 167P
Phenobarbitone, 411
Phenocopying, 9
Phenotype, 466
Phenytoin, 156P, 168P
Physical exercise, 63
Pituitary-adrenal axis, 474, 573
Placenta, 237
Plasma and CSF concentrations, 271
Plasma cortisol, 521
Plasma protein binding, 143
Platelet aggregation, 63
Platelets, 80
Poisson distribution, 401
Polymorphic oxidation, 466
Poor metaboliser, 243
Population pharmacokinetics, 453
Postmarketing surveillance, 229
Postoperative analgesia, 533
Pravastatin, 513
Pre-emptive analgesia, 533
Prednisolone, 441
Prescribing, 489
Primary care, 489
Proguanil, 169P
Propranolol, 9, 480
6 (*n*-propyl)-chromone-2-carboxylic acid, 159P
Prostacyclin, 57
Protein binding, 125, 179P
Proteresis, 389
Psychomotor effects, 363

Quinapril, 117
Quinidine, 23
Quinine, 205

Racemate, 373
Ranitidine bismuth citrate, 577
Ranitidine hydrochloride, 577
Receptor, 417
Recombinant-human growth hormone, 177P
Recovery, 533
Rectal application, 83
Regioselective *n*-alkyl hydroxylation, 159P
Reliability, 474
Renin-angiotensin system, 139, 329
Reproducibility, 480
Risk, 229

Safety assessment of marketed medicines, 93
SAMM guidelines, 95
Salbutamol, 103
Saline (placebo), 533
Saquinavir, 162P
Scaling factors, 177P
Selectivity, 103
Sensitivity, 229
Serotonin antagonist, 151
Serotonin-specific reuptake inhibitors, 23
Sertraline, 23
Sinhalese, 466

Skin, 164P
Skin absorption, 163P
Slow-release formulation, 213
Sodium excretion, 265
Somatostatin analogue, 213
Sparteine, 463
Species differences, 179P
Spectral analysis, 109
Spontaneous reporting, 401
Stavudine, 405
Stereoselectivity, 221
Substance P, 307
Sufentanil, 369
Sulphamethoxazole hydroxylamine, 147
Sulphamethoxazole pharmacokinetics, 147
Sulphaphenazole, 174P
Sulphonamides, 579
Sulphoxidation, 167P
Superficial veins, 181, 289
Suppression, 521
Sustained release, 83
Synovial fluid kinetics, 349
Systemic bioavailability, 527

Tacrine, 15
Talinolol, 480
Tamoxifen, 165P
Teratogenicity, 229
Testosterone hydroxylation, 164P
Theophylline, 178P
Therapeutic drug monitoring, 453, 567
Thiol, 53
Thiopurine methyltransferase, 1
Throat anaesthesia, 533
Tissue distribution, 156P
Tolerance, 161P, 505
Triazole, 77
Turkish population, 463

Urine cortisol, 521

Valproate, 411
Variability, 109
Veins, 199
Venoconstriction, 181
Venodilatation, 181
Venous compliance, 181, 289
Ventilation, 71
Vinpocetine, 143

ZD2079, 161P
Zamifenacin, 179P
Zidovudine, 166P, 323
Zopiclone, 363